[fusion_builder_container hundred_percent=”no” hundred_percent_height=”no” hundred_percent_height_scroll=”no” hundred_percent_height_center_content=”yes” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” status=”published” publish_date=”” class=”” id=”” link_color=”” link_hover_color=”” border_color=”” border_style=”solid” margin_top=”” margin_bottom=”20px” padding_top=”” padding_right=”” padding_bottom=”” padding_left=”” gradient_start_color=”” gradient_end_color=”” gradient_start_position=”0″ gradient_end_position=”100″ gradient_type=”linear” radial_direction=”center center” linear_angle=”180″ background_color=”” background_image=”” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” enable_mobile=”no” parallax_speed=”0.3″ background_blend_mode=”none” video_mp4=”” video_webm=”” video_ogv=”” video_url=”” video_aspect_ratio=”16:9″ video_loop=”yes” video_mute=”yes” video_preview_image=”” filter_hue=”0″ filter_saturation=”100″ filter_brightness=”100″ filter_contrast=”100″ filter_invert=”0″ filter_sepia=”0″ filter_opacity=”100″ filter_blur=”0″ filter_hue_hover=”0″ filter_saturation_hover=”100″ filter_brightness_hover=”100″ filter_contrast_hover=”100″ filter_invert_hover=”0″ filter_sepia_hover=”0″ filter_opacity_hover=”100″ filter_blur_hover=”0″ type=”legacy”][fusion_builder_row][fusion_builder_column type=”1_1″ layout=”1_1″ background_position=”left top” background_color=”” border_color=”” border_style=”solid” border_position=”all” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding_top=”” padding_right=”” padding_bottom=”” padding_left=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” center_content=”no” last=”true” min_height=”” hover_type=”none” link=”” border_sizes_top=”” border_sizes_bottom=”” border_sizes_left=”” border_sizes_right=”” first=”true”][fusion_imageframe image_id=”4457|full” max_width=”” style_type=”” blur=”” stylecolor=”” hover_type=”none” bordersize=”” bordercolor=”” borderradius=”” align=”none” lightbox=”no” gallery_id=”” lightbox_image=”” lightbox_image_id=”” alt=”” link=”” linktarget=”_self” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” animation_type=”” animation_direction=”left” animation_speed=”0.3″ animation_offset=”” filter_hue=”0″ filter_saturation=”100″ filter_brightness=”100″ filter_contrast=”100″ filter_invert=”0″ filter_sepia=”0″ filter_opacity=”100″ filter_blur=”0″ filter_hue_hover=”0″ filter_saturation_hover=”100″ filter_brightness_hover=”100″ filter_contrast_hover=”100″ filter_invert_hover=”0″ filter_sepia_hover=”0″ filter_opacity_hover=”100″ filter_blur_hover=”0″]https://twolabs.com/wp-content/uploads/2020/05/COVID19VaccineUpdate-HeaderImage-TwoLabs-0420v1-2.png[/fusion_imageframe][fusion_separator style_type=”default” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” sep_color=”” top_margin=”” bottom_margin=”30px” border_size=”” icon=”” icon_size=”” icon_circle=”” icon_circle_color=”” width=”” alignment=”center” /][fusion_text columns=”” column_min_width=”” column_spacing=”” rule_style=”default” rule_size=”” rule_color=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” animation_type=”” animation_direction=”left” animation_speed=”0.3″ animation_offset=””]
Our team took a look at the most recent pharmaceutical developments from the week, including where we are with treatment options and how manufacturers are racing to find an effective treatment for COVID-19.
[/fusion_text][fusion_separator style_type=”default” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” sep_color=”” top_margin=”” bottom_margin=”30px” border_size=”” icon=”” icon_size=”” icon_circle=”” icon_circle_color=”” width=”” alignment=”center” /][fusion_title title_type=”text” rotation_effect=”bounceIn” display_time=”1200″ highlight_effect=”circle” loop_animation=”off” highlight_width=”9″ highlight_top_margin=”0″ before_text=”” rotation_text=”” highlight_text=”” after_text=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” content_align=”left” size=”2″ font_size=”” animated_font_size=”” fusion_font_family_title_font=”” fusion_font_subset_title_font=”” fusion_font_variant_title_font=”” line_height=”” letter_spacing=”” margin_top=”” margin_bottom=”20px” margin_top_mobile=”” margin_bottom_mobile=”” text_color=”” animated_text_color=”” highlight_color=”” style_type=”default” sep_color=”” animation_type=”” animation_direction=”left” animation_speed=”0.3″ animation_offset=”” margin_top_small=”” margin_bottom_small=””]
COVID-19 has had significant effects across the healthcare system
[/fusion_title][fusion_code]
    <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tbody>
            <tr>
                <td style="border: none;padding:0;padding-bottom:10px; " width="48%">
                   <h4 style="margin-bottom:0;">STAKEHOLDER:</h4>
                </td>
                <td width="4%" style="border:none;padding:0;"> </td>
                <td style="border: none;padding:0;padding-bottom:10px; " width="48%">
                   <h4 style="margin-bottom:0;">TAKEAWAYS:</h4>
                </td>
            </tr>
            <tr>
                <td style="background: #559cbe; border: none; color: #ffffff;padding:15px;border-radius:4px" width="48%">
                   <p style="margin-bottom:10px;"><b>PATIENTS / PHYSICIANS</b></p>
                    
                    <ul style="margin-top:10px;margin-bottom:0;padding-left:20px;font-size:14px;line-height:17px;">
                        <li style="margin-bottom:3px;">Coronavirus has infected millions of patients worldwide</li>
                        <li style="margin-bottom:3px;">Physicians and pharmacists are seeing increases in workload</li>
                    </ul>
                </td>
                <td width="4%" style="border:none;padding:0;padding-right:4px"><img src="https://twolabs.com/wp-content/uploads/2020/05/ArrowBlue.png" alt="" style="width:100%"></td>
                <td style="background: rgba(85, 156, 190, 0.2); border: none;padding:15px;border-radius:4px;color:#559cbe;font-weight:bold;" width="48%">Treating COVID-19 patients is a top priority, but it will also remain important to treat other chronic conditions
</td>
            </tr>
            <tr>
                <td style="border:none;height:5px;padding:0;padding:0;"></td>
                <td style="border:none;height:5px;padding:0;"></td>
                <td style="border:none;height:5px;padding:0;"></td>
            </tr>
            <tr>
                <td style="background: #e5a04d; border: none; color: #ffffff;padding:15px;border-radius:4px" width="48%">
                   <p style="margin-bottom:10px;"><b>PAYERS</b></p>
                    
                    <ul style="margin-top:10px;margin-bottom:0;padding-left:20px;font-size:14px;line-height:17px;">
                        <li style="margin-bottom:3px;">Payers are moving to virtual P&T committee meetings, but meetings are not being delayed</li>
                        <li style="margin-bottom:3px;">P&T conversations are being limited to business-critical issues</li>
                        <li style="margin-bottom:3px;">Health plans may be temporarily lifting some prior authorization criteria in certain scenarios</li>
                    </ul>
                </td>
                <td width="4%" style="border:none;padding:0;padding-right:4px"><img src="https://twolabs.com/wp-content/uploads/2020/05/ArrowOrange.png" alt="" style="width:100%"></td>
                <td style="background: rgba(229, 160, 77, 0.2); border: none;padding:15px;border-radius:4px;color:#e5a04d;font-weight:bold;" width="48%">Manufactures can expect P&T review cycle to remain as is, but should consider bringing the most critical business issues into meetings

</td>
            </tr>
            <tr>
                <td style="border:none;height:5px;padding:0;"></td>
                <td style="border:none;height:5px;padding:0;"></td>
                <td style="border:none;height:5px;padding:0;"></td>
            </tr>
            <tr>
                <td style="background: #365072; border: none; color: #ffffff;padding:15px;border-radius:4px" width="48%">
                   <p style="margin-bottom:10px;"><b>SUPPLIERS / LOGISTICAL</b></p>
                    
                    <ul style="margin-top:10px;margin-bottom:0;padding-left:20px;font-size:14px;line-height:17px;">
                        <li style="margin-bottom:3px;">US market heavily relies on China and India for active pharmaceutical ingredients (API) exports for generics and will likely work to reduce reliance in the future</li>
                        <li style="margin-bottom:3px;">Supply shortages</li>
                        <li style="margin-bottom:3px;">Patients stockpiling drugs</li>
                    </ul>
                </td>
                <td width="4%" style="border:none;padding:0;padding-right:4px"><img src="https://twolabs.com/wp-content/uploads/2020/05/ArrowNavy.png" alt="" style="width:100%"></td>
                <td style="background: rgba(54, 80, 114, 0.2); border: none;padding:15px;border-radius:4px;color:#365072;font-weight:bold;" width="48%">Manufacturers will need to find new ways to navigate supply chain issues and generic ingredient sourcing and may need to increase resources dedicated toward generics

</td>
            </tr>
            <tr>
                <td style="border:none;height:5px;padding:0;"></td>
                <td style="border:none;height:5px;padding:0;"></td>
                <td style="border:none;height:5px;padding:0;"></td>
            </tr>
            <tr>
                <td style="background: #aeb15e; border: none; color: #ffffff;padding:15px;border-radius:4px" width="48%">
                   <p style="margin-bottom:10px;"><b>MEDICARE / MEDICAID</b></p>
                    
                    <ul style="margin-top:10px;margin-bottom:0;padding-left:20px;font-size:14px;line-height:17px;">
                        <li style="margin-bottom:3px;">Physicians treating COVID-19 Medicare patients through telehealth will be reimbursed based on their usual site of care (e.g., a physician from a clinic setting will be reimbursed at the non-facility rate)</li>
                        <li style="margin-bottom:3px;">Medicare is allowing for real-time patient/physician audio and video technology during COVID-19</li>
                        <li style="margin-bottom:3px;">Medicare payments will remain the same for Part B medications</li>
                    </ul>
                </td>
                <td width="4%" style="border:none;padding:0;padding-right:4px"><img src="https://twolabs.com/wp-content/uploads/2020/05/ArrowGreen.png" alt="" style="width:100%"></td>
                <td style="background: rgba(174, 177, 94, 0.2); border: none;padding:15px;border-radius:4px;color:#aeb15e;font-weight:bold;" width="48%">Medicare reimbursement will not change as a result of COVID-19 and Medicare patients will maintain access to doctor visits and critical medications

</td>
            </tr>
            <tr>
                <td style="border:none;height:5px;padding:0;"></td>
                <td style="border:none;height:5px;padding:0;"></td>
                <td style="border:none;height:5px;padding:0;"></td>
            </tr>
            <tr>
                <td style="background: #666666; border: none; color: #ffffff;padding:15px;border-radius:4px" width="48%">
                   <p style="margin-bottom:10px;"><b>PHARMA / BIOTECH</b></p>
                    
                    <ul style="margin-top:10px;margin-bottom:0;padding-left:20px;font-size:14px;line-height:17px;">
                        <li style="margin-bottom:3px;">Several companies are expediting clinical trials to find an effective vaccine for COVID-19</li>
                        <li style="margin-bottom:3px;">There are several potential drug treatment candidates</li>
                        <li style="margin-bottom:3px;">Some clinical trials for non COVID-19 treatments are being put on hold</li>
                        <li style="margin-bottom:3px;">Sales representatives unable to visit physician offices</li>
                    </ul>
                </td>
                <td width="4%" style="border:none;padding:0;padding-right:4px"><img src="https://twolabs.com/wp-content/uploads/2020/05/ArrowGray.png" alt="" style="width:100%"></td>
                <td style="background: #DDDDDD; border: none;padding:15px;border-radius:4px;color:#666666;font-weight:bold;" width="48%">It will remain important to prioritize innovative therapies as well as treatments and vaccines for COVID-19

</td>
            </tr>
        </tbody>
    </table>
[/fusion_code][fusion_separator style_type=”default” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” sep_color=”” top_margin=”” bottom_margin=”60px” border_size=”” icon=”” icon_size=”” icon_circle=”” icon_circle_color=”” width=”” alignment=”center” /][fusion_separator style_type=”single solid” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” sep_color=”” top_margin=”” bottom_margin=”30px” border_size=”” icon=”” icon_size=”” icon_circle=”” icon_circle_color=”” width=”” alignment=”center” /][fusion_separator style_type=”default” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” sep_color=”” top_margin=”” bottom_margin=”25px” border_size=”” icon=”” icon_size=”” icon_circle=”” icon_circle_color=”” width=”” alignment=”center” /][fusion_title title_type=”text” rotation_effect=”bounceIn” display_time=”1200″ highlight_effect=”circle” loop_animation=”off” highlight_width=”9″ highlight_top_margin=”0″ before_text=”” rotation_text=”” highlight_text=”” after_text=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” content_align=”left” size=”2″ font_size=”” animated_font_size=”” fusion_font_family_title_font=”” fusion_font_subset_title_font=”” fusion_font_variant_title_font=”” line_height=”” letter_spacing=”” margin_top=”” margin_bottom=”20px” margin_top_mobile=”” margin_bottom_mobile=”” text_color=”” animated_text_color=”” highlight_color=”” style_type=”default” sep_color=”” animation_type=”” animation_direction=”left” animation_speed=”0.3″ animation_offset=”” margin_top_small=”” margin_bottom_small=””]
There are several vaccines and drug candidates in development which could help prevent or treat COVID-19
[/fusion_title][fusion_title title_type=”text” rotation_effect=”bounceIn” display_time=”1200″ highlight_effect=”circle” loop_animation=”off” highlight_width=”9″ highlight_top_margin=”0″ before_text=”” rotation_text=”” highlight_text=”” after_text=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” content_align=”left” size=”4″ font_size=”” animated_font_size=”” fusion_font_family_title_font=”” fusion_font_subset_title_font=”” fusion_font_variant_title_font=”” line_height=”” letter_spacing=”” margin_top=”” margin_bottom=”” margin_top_mobile=”” margin_bottom_mobile=”” text_color=”” animated_text_color=”” highlight_color=”” style_type=”default” sep_color=”” animation_type=”” animation_direction=”left” animation_speed=”0.3″ animation_offset=”” margin_top_small=”” margin_bottom_small=””]
VACCINES*
[/fusion_title][fusion_separator style_type=”default” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” sep_color=”” top_margin=”” bottom_margin=”20″ border_size=”” icon=”” icon_size=”” icon_circle=”” icon_circle_color=”” width=”” alignment=”center” /][fusion_text][fusion_table fusion_table_type=”2″ fusion_table_rows=”4″ fusion_table_columns=”2″ hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” animation_type=”” animation_direction=”left” animation_speed=”0.3″ animation_offset=””]
| INO-4800 (Inovio) | Inovio said its Phase 1 U.S. clinical test for INO-4800 is fully enrolled with all 40 healthy volunteers receiving their first dose, with interim immune responses and safety results expected in late June |
| Ad5-nCoV (CanSino) | Genetically engineered vaccine building off the platform used to develop an Ebola vaccine; this vaccine recently entered Phase 2 clinical trials |
| mRNA-1273 (Moderna) | The phase 2 study is expected to begin in the second quarter. That will evaluate the safety and any adverse reactions and immune responses of two mRNA-1273 vaccinations given 28 days apart |
| Pfizer & BioNTech (BNT-162) | Pfizer announced a joint venture with BioNtech to develop and distribute BioNTech’s mRNA based COVID-19 vaccine candidate BNT-162 |
| Dynavax | Working with the University of Queensland to develop a vaccine for COVID-19. It would make its vaccine adjuvant technology available to other companies working on a vaccine through CEPI |
| Curevac | Curevac has begun work on its COVID-19 vaccine and plans to enter clinical trials with its lead vaccine candidate in June 2020 |
[/fusion_table][/fusion_text][fusion_separator style_type=”default” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” sep_color=”” top_margin=”” bottom_margin=”30px” border_size=”” icon=”” icon_size=”” icon_circle=”” icon_circle_color=”” width=”” alignment=”center” /][fusion_title title_type=”text” rotation_effect=”bounceIn” display_time=”1200″ highlight_effect=”circle” loop_animation=”off” highlight_width=”9″ highlight_top_margin=”0″ before_text=”” rotation_text=”” highlight_text=”” after_text=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” content_align=”left” size=”4″ font_size=”” animated_font_size=”” fusion_font_family_title_font=”” fusion_font_subset_title_font=”” fusion_font_variant_title_font=”” line_height=”” letter_spacing=”” margin_top=”” margin_bottom=”” margin_top_mobile=”” margin_bottom_mobile=”” text_color=”” animated_text_color=”” highlight_color=”” style_type=”default” sep_color=”” animation_type=”” animation_direction=”left” animation_speed=”0.3″ animation_offset=”” margin_top_small=”” margin_bottom_small=””]
TREATMENTS
[/fusion_title][fusion_separator style_type=”default” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” sep_color=”” top_margin=”” bottom_margin=”20″ border_size=”” icon=”” icon_size=”” icon_circle=”” icon_circle_color=”” width=”” alignment=”center” /][fusion_text][fusion_table fusion_table_type=”2″ fusion_table_rows=”7″ fusion_table_columns=”2″ hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” animation_type=”” animation_direction=”left” animation_speed=”0.3″ animation_offset=””]
| Remdesivir (Gilead) | Data from the open-label SIMPLE trial, show that remdesivir may accelerate recovery rates among patients with advanced Covid-19 |
| Chloroquine (Rising Pharmaceuticals) | Donated Hydroxychloroquine tablets in support of a Phase 2 trial exploring hydroxychloroquine as preventive treatment for COVID-19 in patients with cancer who are receiving radiation therapy |
| Actemra (Roche) | FDA approved a Phase 3 trial of Actemra (tocilizumab) in COVID-19 patients with pneumonia |
| Kaletra/Aluvia (AbbVie) | An HIV medication that showed promise but failed to meet endpoints in an early study; however, it is possible that this drug could be more effective if administered sooner after disease onset |
| Kevzara (Sanofi/Regeneron) | Kevzara delivered disappointing results in their clinical studies, which would have helped ease the immune system’s overreaction to the virus |
| TAKE-888 (Takeda) | A blood plasma derived therapy in development; this treatment depends on the company’s ability to obtain enough blood plasma of recovered patients |
| Vir (VIR-7831 & VIR-7832) | The pair’s (GSK has invested $250 million) immediate focus will be VIR-7831 and VIR-7832 in which they plan to move the candidates into a phase 2 clinical trial in the next three to five months |
| Eli Lilly & AbCellera | Lilly is working with biotechnology company AbCellera, to develop a treatment based on antibodies present in the blood of patients who’ve recovered from Covid-19, trials to start end of May |
| Emergent BioSolutions | Begun the development of two candidate hyperimmune products against the disease. It will aim to leverage the immune response in order to combat COVID-19 and are derived from antibodies |
| Novartis (canakinumab) | Novartis announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. Treat a type of immune overreaction in people with COVID-19 pneumonia |
| Novavax Inc (NVX-CoV2373) | The company has now identified its lead vaccine candidate, NVX-CoV2373 and will initiate a first-in-human trial |
| Incyte (Jakafi) | Plan to test Jakafi in a second phase 3 trial for COVID-19 patients with acute respiratory distress syndrome. Jakafi’s safety and efficacy over standard of care in ARDS patients who need ventilators |
[/fusion_table][/fusion_text][fusion_separator style_type=”default” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” sep_color=”” top_margin=”” bottom_margin=”30px” border_size=”” icon=”” icon_size=”” icon_circle=”” icon_circle_color=”” width=”” alignment=”center” /][fusion_text columns=”” column_min_width=”” column_spacing=”” rule_style=”default” rule_size=”” rule_color=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” animation_type=”” animation_direction=”left” animation_speed=”0.3″ animation_offset=””]
*Non-exhaustive list. As of May 17, there were a total of 82 active Phase II trials; J&J/Janssen and Sanofi Pasteur are also developing vaccines.
[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container][fusion_builder_container hundred_percent=”no” hundred_percent_height=”no” hundred_percent_height_scroll=”no” hundred_percent_height_center_content=”yes” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” status=”published” publish_date=”” class=”” id=”” link_color=”” link_hover_color=”” border_color=”” border_style=”solid” margin_top=”20px” margin_bottom=”” padding_top=”” padding_right=”10%” padding_bottom=”” padding_left=”10%” gradient_start_color=”” gradient_end_color=”” gradient_start_position=”0″ gradient_end_position=”100″ gradient_type=”linear” radial_direction=”center center” linear_angle=”180″ background_color=”” background_image=”” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” enable_mobile=”no” parallax_speed=”0.3″ background_blend_mode=”none” video_mp4=”” video_webm=”” video_ogv=”” video_url=”” video_aspect_ratio=”16:9″ video_loop=”yes” video_mute=”yes” video_preview_image=”” filter_hue=”0″ filter_saturation=”100″ filter_brightness=”100″ filter_contrast=”100″ filter_invert=”0″ filter_sepia=”0″ filter_opacity=”100″ filter_blur=”0″ filter_hue_hover=”0″ filter_saturation_hover=”100″ filter_brightness_hover=”100″ filter_contrast_hover=”100″ filter_invert_hover=”0″ filter_sepia_hover=”0″ filter_opacity_hover=”100″ filter_blur_hover=”0″ type=”legacy”][fusion_builder_row][fusion_builder_column type=”1_1″ layout=”1_1″ spacing=”” center_content=”no” link=”” target=”_self” min_height=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” hover_type=”none” border_color=”” border_style=”solid” border_position=”all” border_radius=”” box_shadow=”no” dimension_box_shadow=”” box_shadow_blur=”0″ box_shadow_spread=”0″ box_shadow_color=”” box_shadow_style=”” padding_top=”” padding_right=”” padding_bottom=”” padding_left=”” margin_top=”” margin_bottom=”” background_type=”single” gradient_start_color=”” gradient_end_color=”” gradient_start_position=”0″ gradient_end_position=”100″ gradient_type=”linear” radial_direction=”center center” linear_angle=”180″ background_color=”” background_image=”” background_image_id=”” background_position=”left top” background_repeat=”no-repeat” background_blend_mode=”none” animation_type=”” animation_direction=”left” animation_speed=”0.3″ animation_offset=”” filter_type=”regular” filter_hue=”0″ filter_saturation=”100″ filter_brightness=”100″ filter_contrast=”100″ filter_invert=”0″ filter_sepia=”0″ filter_opacity=”100″ filter_blur=”0″ filter_hue_hover=”0″ filter_saturation_hover=”100″ filter_brightness_hover=”100″ filter_contrast_hover=”100″ filter_invert_hover=”0″ filter_sepia_hover=”0″ filter_opacity_hover=”100″ filter_blur_hover=”0″ last=”true” border_sizes_top=”0″ border_sizes_bottom=”0″ border_sizes_left=”0″ border_sizes_right=”0″ first=”true”][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container][fusion_builder_container hundred_percent=”no” hundred_percent_height=”no” hundred_percent_height_scroll=”no” hundred_percent_height_center_content=”yes” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” status=”published” publish_date=”” class=”” id=”” link_color=”” link_hover_color=”” border_color=”” border_style=”solid” margin_top=”60px” margin_bottom=”” padding_top=”40px” padding_right=”10%” padding_bottom=”0px” padding_left=”10%” gradient_start_color=”” gradient_end_color=”” gradient_start_position=”0″ gradient_end_position=”100″ gradient_type=”linear” radial_direction=”center center” linear_angle=”180″ background_color=”#f7f7f7″ background_image=”” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” enable_mobile=”no” parallax_speed=”0.3″ background_blend_mode=”none” video_mp4=”” video_webm=”” video_ogv=”” video_url=”” video_aspect_ratio=”16:9″ video_loop=”yes” video_mute=”yes” video_preview_image=”” filter_hue=”0″ filter_saturation=”100″ filter_brightness=”100″ filter_contrast=”100″ filter_invert=”0″ filter_sepia=”0″ filter_opacity=”100″ filter_blur=”0″ filter_hue_hover=”0″ filter_saturation_hover=”100″ filter_brightness_hover=”100″ filter_contrast_hover=”100″ filter_invert_hover=”0″ filter_sepia_hover=”0″ filter_opacity_hover=”100″ filter_blur_hover=”0″ type=”legacy”][fusion_builder_row][fusion_builder_column type=”1_1″ layout=”1_1″ spacing=”” center_content=”no” link=”” target=”_self” min_height=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” hover_type=”none” border_color=”” border_style=”solid” border_position=”all” border_radius=”” box_shadow=”no” dimension_box_shadow=”” box_shadow_blur=”0″ box_shadow_spread=”0″ box_shadow_color=”” box_shadow_style=”” padding_top=”” padding_right=”” padding_bottom=”” padding_left=”” margin_top=”” margin_bottom=”” background_type=”single” gradient_start_color=”” gradient_end_color=”” gradient_start_position=”0″ gradient_end_position=”100″ gradient_type=”linear” radial_direction=”center center” linear_angle=”180″ background_color=”” background_image=”” background_image_id=”” background_position=”left top” background_repeat=”no-repeat” background_blend_mode=”none” animation_type=”” animation_direction=”left” animation_speed=”0.3″ animation_offset=”” filter_type=”regular” filter_hue=”0″ filter_saturation=”100″ filter_brightness=”100″ filter_contrast=”100″ filter_invert=”0″ filter_sepia=”0″ filter_opacity=”100″ filter_blur=”0″ filter_hue_hover=”0″ filter_saturation_hover=”100″ filter_brightness_hover=”100″ filter_contrast_hover=”100″ filter_invert_hover=”0″ filter_sepia_hover=”0″ filter_opacity_hover=”100″ filter_blur_hover=”0″ last=”true” border_sizes_top=”0″ border_sizes_bottom=”0″ border_sizes_left=”0″ border_sizes_right=”0″ first=”true”][fusion_text columns=”” column_min_width=”” column_spacing=”” rule_style=”default” rule_size=”” rule_color=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” animation_type=”” animation_direction=”left” animation_speed=”0.3″ animation_offset=””]
Do you need help determining the impact of COVID-19 on your launch and how to navigate forward? Click the button below to get in touch with our expert team.
[/fusion_text][fusion_code]PGlmcmFtZSBzcmM9Imh0dHBzOi8vZ28udHdvbGFicy5jb20vbC84MDYyMTMvMjAyMC0wMy0yNy96M212IiB3aWR0aD0iMTAwJSIgaGVpZ2h0PSI1MDAiIHR5cGU9InRleHQvaHRtbCIgZnJhbWVib3JkZXI9IjAiIGFsbG93VHJhbnNwYXJlbmN5PSJ0cnVlIiBzdHlsZT0iYm9yZGVyOiAwIj48L2lmcmFtZT4=[/fusion_code][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]